CA2224715A1 - Macrolides - Google Patents

Macrolides Download PDF

Info

Publication number
CA2224715A1
CA2224715A1 CA002224715A CA2224715A CA2224715A1 CA 2224715 A1 CA2224715 A1 CA 2224715A1 CA 002224715 A CA002224715 A CA 002224715A CA 2224715 A CA2224715 A CA 2224715A CA 2224715 A1 CA2224715 A1 CA 2224715A1
Authority
CA
Canada
Prior art keywords
formula
macrolide
ring
compound
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002224715A
Other languages
English (en)
French (fr)
Inventor
Theodor Fehr
Lukas Oberer
Valerie Quesniaux Ryffel
Jean- Jacques Sanglier
Walter Schuler
Richard Sedrani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513596.8A external-priority patent/GB9513596D0/en
Priority claimed from GBGB9515495.1A external-priority patent/GB9515495D0/en
Application filed by Individual filed Critical Individual
Publication of CA2224715A1 publication Critical patent/CA2224715A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002224715A 1995-07-04 1996-07-04 Macrolides Abandoned CA2224715A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9513596.8 1995-07-04
GBGB9513596.8A GB9513596D0 (en) 1995-07-04 1995-07-04 Organic compounds
GB9515495.1 1995-07-28
GBGB9515495.1A GB9515495D0 (en) 1995-07-28 1995-07-28 Organic compounds

Publications (1)

Publication Number Publication Date
CA2224715A1 true CA2224715A1 (en) 1997-01-23

Family

ID=26307320

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002224715A Abandoned CA2224715A1 (en) 1995-07-04 1996-07-04 Macrolides

Country Status (17)

Country Link
EP (1) EP0836616A1 (ja)
JP (1) JPH11509092A (ja)
KR (1) KR19990028724A (ja)
CN (1) CN1193979A (ja)
AR (1) AR006514A1 (ja)
AU (1) AU708004B2 (ja)
BR (1) BR9609324A (ja)
CA (1) CA2224715A1 (ja)
CO (1) CO4750713A1 (ja)
CZ (1) CZ424297A3 (ja)
HU (1) HUP9802320A3 (ja)
IL (1) IL122844A0 (ja)
NO (1) NO980016L (ja)
PL (1) PL324346A1 (ja)
SK (1) SK498A3 (ja)
TR (1) TR199800001T1 (ja)
WO (1) WO1997002285A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
RU2427372C2 (ru) 2005-06-17 2011-08-27 Новартис Аг Применение санглиферина для лечения вируса гепатита с
US8067024B2 (en) 2006-02-10 2011-11-29 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
CN101289440B (zh) * 2007-06-29 2010-08-25 中国热带农业科学院热带生物技术研究所 一种多烯大环类化合物及其制备方法与应用
CN102224242B (zh) * 2008-09-24 2014-09-24 中国科学院上海有机化学研究所 新基因簇
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
BR112012019866A8 (pt) 2010-02-09 2017-12-26 Biotica Tech Limited Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
GB201008123D0 (en) 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
CA3028414C (en) 2010-12-20 2021-01-26 Neurovive Pharmaceutical Ab Sanglifehrin derivatives and methods for their production
JO3063B1 (ar) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
PT2861604T (pt) * 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
AR091279A1 (es) * 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
MX2014014768A (es) * 2012-06-08 2015-05-11 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae.
EP3541388A1 (en) 2016-11-18 2019-09-25 Neurovive Pharmaceutical AB Use of sanglifehrin macrocyclic analogues as anticancer compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9318144D0 (en) * 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
WO1995015328A1 (en) * 1993-11-30 1995-06-08 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements

Also Published As

Publication number Publication date
AU708004B2 (en) 1999-07-29
JPH11509092A (ja) 1999-08-17
TR199800001T1 (xx) 1998-04-21
BR9609324A (pt) 1999-05-25
AR006514A1 (es) 1999-09-08
AU6519396A (en) 1997-02-05
CZ424297A3 (cs) 1998-04-15
KR19990028724A (ko) 1999-04-15
IL122844A0 (en) 1998-08-16
PL324346A1 (en) 1998-05-25
SK498A3 (en) 1998-07-08
NO980016L (no) 1998-03-02
MX9800217A (es) 1998-07-31
NO980016D0 (no) 1998-01-02
HUP9802320A2 (hu) 1999-02-01
HUP9802320A3 (en) 1999-03-29
EP0836616A1 (en) 1998-04-22
CN1193979A (zh) 1998-09-23
CO4750713A1 (es) 1999-03-31
WO1997002285A1 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
CA2224715A1 (en) Macrolides
US6124453A (en) Macrolides
US5484799A (en) Antifungal dorrigocin derivatives
US5441977A (en) 21-norrapamycin
CA2066499A1 (en) Lipophilic macrolide useful as an immunosuppressant
KR20070009578A (ko) 마크롤라이드 및 이의 제조 방법
EP1720548A1 (en) Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
NZ250344A (en) Zearalenone analogues, their preparation from a fungal fermentation, the fungal strain, and pharmaceutical compositions
US5643869A (en) Pipecolic acid-containing peptolides, their preparation and pharmaceutical compositions containing them
CA2136234A1 (en) Enantiomeric dynemicin analogs, preparation and use thereof
AU689207B2 (en) Indole diterpene alkaloid compounds
US5284947A (en) Multiple drug resistance-attenuating compounds
US6812245B2 (en) Polycylic xanthones and their use
AU621857B2 (en) Novel compounds, process for the preparation thereof and uses thereof
MXPA98000217A (en) Macroli
MXPA02000173A (es) Nuevos alcaloides de indolocarbazola de un actinomiceto marino.
SK65698A3 (en) Cyclopeptolides
WO1996032388A1 (en) Antheliatin, zahavin a and zahavin b: new cytotoxic xenicane diterpenes
JP2003512448A (ja) 芳香族ジケト誘導体、その製造方法および医薬としてのその使用
JPH0570470A (ja) 生理活性物質カンレマイシンｃ、その製造法及びその薬学的用途
JP2003523346A (ja) プルラフラビンおよびその誘導体、それらの製造方法および使用
WO2000027839A1 (en) Rameswaralide and rameswaralide derivatives
JPH06343480A (ja) Ｓｆ２３１５ａの製造法及びその薬学的用途
AU1774099A (en) Cytotoxic alkaloid derivatives including asmarine a and b isolated from a sponge
PL164143B1 (pl) Sposób wytwarzania nowych peptolldów zawierających kwas pipekollnowy

Legal Events

Date Code Title Description
FZDE Discontinued